CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 17 enrolled
Drug / intervention
Infliximabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04425538
NCT04425538Phase 2Completed
CompareCT.gov

A Phase 2 Trial of Infliximab in Coronavirus Disease 2019 (COVID-19).

Tufts Medical Center·interventional·Posted Jun 11, 2020·Updated Apr 20, 2022

In Brief

A Phase 2 clinical trial evaluating Infliximab for COVID-19. Completed, enrolled 17 participants across 1 site.

Detailed Summary

The investigators hypothesize that early institution of TNFα inhibitor therapy in patients with severe COVID-19 infections will prevent further clinical deterioration and reduce the need for advanced cardiorespiratory support and early mortality. To address this hypothesis, a prospective, single center, phase 2 trial is proposed to assess the efficacy of infliximab or infliximab-abda in hospitalized adult patients with severe or critical COVID-19. Observations from this study will inform the conduct of prospective randomized controlled studies to follow.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19
CountriesUnited States
CollaboratorsNational Institutes of Health (NIH)

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedJun 11, 2020
Enrollment StartJun 1, 2020
Primary CompletionJan 22, 2021
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 6.1 years ago

Interventions

Infliximabdrug

Either infliximab or infliximab-abda will be used at the discretion of the investigator